Through the acquisition of Penn Pharma, PCI is proud of a long and successful track record in manufacturing products requiring containment resources.
Our facilities and capability for safely handling potent products enables the safe development and commercial supply of products with an OEL down to 0.01 μg/m3. Investment in leading-edge engineered technology places us at the forefront of the industry and enables the provision of a fully comprehensive service for solid dose potent dosage forms. The development facility created by Penn Pharma for tablets and capsules utilizes processing technologies including roller compaction, high shear granulation and fluid bed drying that are common with our larger scale production unit.
Designed from first principles to meet the growing demand for safe and compliant production of tablets and capsules containing highly potent molecules, our contained manufacturing facility uses the latest generation contained equipment and systems and automated clean in place or wash off-line systems. Equipped to meet the needs of development, clinical batch and commercial batch requirements, our facility is able to produce batches from development scale (1kg), through clinical scale (10kg) and up to commercial (120kg) batches of capsules or film coated tablets. This design-for-manufacture philosophy and use of geometric scale-up ensures consistent reproducibility delivering true speed to market for our clients.
Potent drug product manufactured in specially designed contained engineering equipment including:
Contained Operations Summary